Trametinib dimethyl sulfoxide. MAP kinase kinase 1 and 2 (MEK 1/2) inhibitor oncolytic

D. P. Cosgrove

Research output: Contribution to journalReview articlepeer-review


Dysregulation of the Ras/Raf/MEK/ERK signaling pathway (also known as the mitogen-activated protein [MAP] kinase pathway) has been implicated in many types of cancer, including melanoma, pancreas, colon and lung cancer, and this pathway has become an attractive target for therapeutic development. There has been some success in targeting Raf, but previously developed MEK inhibitors have yielded limited clinical benefit. This review focuses on the preclinical and clinical development of trametinib dimethyl sulfoxide (GSK-1120212B), a selective MEK 1/2 inhibitor.

Original languageEnglish (US)
Pages (from-to)847-853
Number of pages7
JournalDrugs of the Future
Issue number12
StatePublished - Dec 2012
Externally publishedYes


  • Cancer
  • GSK-1120212B
  • MAP kinase kinase inhibitor
  • Signaling pathway
  • Trametinib dimethyl sulfoxide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Trametinib dimethyl sulfoxide. MAP kinase kinase 1 and 2 (MEK 1/2) inhibitor oncolytic'. Together they form a unique fingerprint.

Cite this